years. Patients with the dural tail sign, a wide dural base, and hyperostotic bone on pretreatment imaging studies were excluded. Between 1997 and 2004, 394 patients with an intracranial schwannoma received GKS at our institution, and in 35 patients (8.9%) the diagnosis was trigeminal schwannoma. Thirteen of these were excluded (10 for an insufficient follow-up period and three for neurofibromatosis). After these criteria were applied, 22 patients were eligible and their clinical and radiological data were retrospectively reviewed.
Six patients were men and 16 were women. The median age at the time of GKS was 52 years (27-73 years). Facial hypesthesia and trigeminal pain were the most common symptoms (11 patients each). Eight patients had a headache, two had abducent nerve palsy, and one had oculomotor palsy. Tumors were located in the middle and posterior fossae (dumbbell shape; 11 cases), middle fossa only, posterior fossa only (five cases each), and middle fossa with extracranial extension (one case). Eighteen patients (82%) received primary GKS, and four (18%) received GKS after resection. Table 1 summarizes the clinical characteristics and treatment parameters in all patients.
Radiosurgical Techniques
The Leksell Model G Stereotactic frame (Elekta Instruments AB) was applied to the patient's head after induction of local anesthesia. Spoiled gradient recalled echo MR sequences were obtained with and without addition of contrast material. Treatment was planned using the Leksell GammaPlan (Elekta Instruments AB). Multiple-isocenter planning was applied to minimize the radiation exposure of adjacent structures.
The median tumor volume was 4.1 ml (0.2-12.0 ml). The mean tumor margin dose was 13.3 Ϯ 1.3 Gy at an isodose line of 49.9 Ϯ 0.6%, and the maximal dose administered was 26.9 Ϯ 2.7 Gy (mean Ϯ standard deviation). The median number of shots was 11 (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) .
Patients received 10 mg of dexamethasone intravenously before GKS, and 4 mg every 8 hours thereafter, and all were discharged on the day of or 1 day after treatment. Oral prednisolone was prescribed on a tapering schedule over 1 week.
Follow-Up Protocol and Data Analysis
A regular clinical follow-up schedule was offered to all patients, beginning 1 month after GKS. Brain MR images were obtained at the 6-month and 1-year follow-up visits, and thereafter annually scheduled MR imaging was recommended. When a patient complained of aggravating symptoms or showed clinical deterioration, MR imaging was indicated regardless of the schedule. The MR images were reviewed independently by a neuroradiologist for clinical follow-up, and review and volume measurement were performed by the authors. Tumor volumes were calculated using Osiris 3.0 (University Hospital of Geneva).
The median duration of clinical follow-up was 46 months (24-89 months), and the median duration of imaging follow-up was 37 months (24-79 months). Treatment out- 
Results

Oncological Outcomes
Based on serial follow-up MR imaging studies and volumetric analyses, tumor growth was found to be controlled in 21 (95%) of the 22 patients, after a median imaging follow-up period of 37 months (range 24-79 months). Final tumor volumes decreased in 16 patients (73%), were stationary in five (23%), and increased in 1 (4%). After GKS, 11 patients (50%) showed continuous tumor volume reduction, 10 patients (46%) had tumor expansion, and one patient showed virtually no volume change. After an initial tumor expansion in the 10 patients, tumor shrinkage followed in five ( Fig. 1) , tumor volumes became stationary in four, and one patient experienced shrinkage and later regrowth, leading to treatment failure.
Transient tumor volume expansion was significantly more frequent in larger tumors. The initial tumor volume (mean Ϯ standard deviation) was 6.8 Ϯ 3.7 ml in patients with transient volume expansion, whereas it was 2.7 Ϯ 2.4 ml in those without volume expansion (p = 0.01, Student ttest). Nine of the 10 patients with tumor expansion showed central enhancement loss between 6 and 18 months after GKS, which coincided with or preceded tumor expansion (p Ͻ 0.001, Fisher exact test).
In the only case of tumor control failure, marked tumor enlargement with a central enhancement loss was noted at 6 months after GKS, and this caused multiple cranial neuropathies, some of which became permanent. Subsequently, tumor shrinkage followed over 3 years, only to be followed by tumor regrowth at 4 years after GKS. Resection was recommended, but the patient refused because the chief symptom, facial dysesthesia, was well tolerated while the patient continued oral medication.
Functional Outcome
Trigeminal pain responded best to GKS; eight (73%) of 11 patients experienced pain remission. Headaches also responded, and were relieved in five patients (63%). Oculomotor and abducent nerve palsy disappeared in two (67%) of three patients. However, there appears to be little chance of regaining facial sensory function; only three (27%) of 11 patients improved, and trigeminal motor dysfunction, once established with masseter atrophy, did not improve at all. Functional outcomes are summarized in Fig. 2 .
New or Worsening Cranial Neuropathies
New or worsening cranial nerve deficits were observed in six patients (27%); three had permanent and three had transient deficits after radiosurgery. Only one patient with permanent deficits experienced tumor control failure, and tumor volume was eventually reduced or stationary in the other two. Trigeminal pain and abducent nerve palsy were invariably transient, whereas new-onset facial hypesthesia and dysesthesia remained permanent.
Only the presence of a tumor involving the cavernous sinus was found to be related to the emergence of cranial neuropathies, and tumors confined to the posterior or temporal fossae were not associated with the development of cranial neuropathy after GKS (six of 14 compared with 0 of eight cases; p = 0.034, Fisher exact test).
Patients who developed new or worsening cranial nerve deficits were given oral steroids to alleviate symptoms and MR imaging was recommended to evaluate tumor status. preceded volume expansion in two cases and coincided with it in three cases. Tumor expansion proved transient and was followed by shrinkage in four patients, but was continuous in one, in whom it led to control failure. Both central enhancement loss and tumor expansion on followup MR images were significantly related to the emergence of cranial neuropathies (p = 0.033 for each factor, Fisher exact test); Fig. 3 illustrates an exemplary case. The initial tumor volume and prescribed radiation dose showed no significant correlation with cranial nerve deficits after GKS.
Discussion
Direct comparisons of the outcomes of microsurgery and radiosurgery are usually hampered by some limitations. One major problem is that, generally, larger tumors are involved in surgical series than in radiosurgical series. Moreover, most reports on radiosurgery of trigeminal schwannomas, including ours, have only a short-or medium-length follow-up. 7, 11, 15, 20 Because the effects and complications of microsurgery are immediate, whereas those of radiosurgery come insidiously over the following years, long-term results of tumor control and adverse radiation effects should be evaluated. Nevertheless, considering the fact that no controlled studies on the treatment of trigeminal schwannomas have been performed, continuation of the comparative analysis in spite of such limitations is worthwhile.
Trigeminal schwannoma is an overwhelmingly benign neoplasm that can be cured by complete surgical removal. The advancements in microsurgical techniques have made it possible to remove this tumor totally, despite its strategic location at the skull base and its involvement of important neurovascular structures. When McCormick et al. 12 reported that total resection was possible in six of 14 cases of trigeminal schwannoma, although it was a great achievement at the time, they also made it clear that this was not achieved without cost; 12 patients in their series (86%) experienced new-onset permanent cranial neuropathies. Sim- FIG. 3 . Illustrative case. The diagnosis in this 31-year-old man with left facial pain and hypesthesia was trigeminal schwannoma. The initial tumor volume was 3.9 ml, and a marginal dose of 14.0 Gy was prescribed at a 50% isodose line (A). Loss of central enhancement was noticed on MR images obtained 6 months after GKS (3.0 ml; B). The patient noted worsening facial pain and diplopia due to sixth cranial nerve palsy, starting at 7 months after GKS. An MR imaging study obtained at 12 months after GKS showed slight tumor expansion (3.7 ml; C), and the MR image obtained at 18 months after GKS demonstrated a slight reduction (3.0 ml; D). Facial pain and diplopia disappeared 15 months after GKS, and the patient's facial hypesthesia gradually improved thereafter. Follow-up MR images obtained at 24 (E) and 42 months (F) after GKS showed continued shrinkage (1.8 and 1.4 ml, respectively). The patient recovered completely, without deficits. ilarly, in a series by Samii et al., 22 half of the patients had postoperative complications, such as tetraparesis or facial nerve palsy, and three quarters of their patients also experienced loss of or an impaired trigeminal nerve function. Day and Fukushima 2 reported total trigeminal schwannoma resection in 30 of 38 patients, and again loss of trigeminal nerve function was not uncommon; six had new-onset trigeminal hypesthesia, five had trigeminal anesthesia, and 20 had trigeminal motor weakness. Yoshida and Kawase 23 reported that total resection was possible in 17 of 27 patients treated surgically, but that 20 had postoperative complications, mainly cranial neuropathies. Moreover, all 25 patients in a series by Al-Mefty et al. 1 underwent total resection, but surgical complications occurred in 12 patients, and three of these had permanent cranial neuropathies. Thus, surgical complications, especially cranial neuropathies, remain the main obstacle to the radical resection of trigeminal schwannomas, despite improved tumor control outcomes.
Several reports are available on stereotactic radiosurgery for trigeminal schwannomas. Huang et al. 7 described treatment outcomes for GKS in trigeminal schwannoma for 16 patients. After an average follow-up period of 44 months, 100% tumor control and no complications were observed. Mabanta et al. 11 described the outcomes of linear accelerator stereotactic radiosurgery in a series of nonacoustic schwannomas, which included seven patients with trigeminal schwannoma. After an average follow-up period of 32 months the tumor control rate was 100%, but one sixth of patients developed cranial neuropathies in that series. Pollock et al. 20 performed a detailed analysis of treatment outcomes of nonacoustic schwannomas treated with GKS, which included 10 patients with trigeminal schwannoma. All trigeminal schwannomas were controlled after a mean of 43 months, except in one case with malignant histological findings. However, permanent cranial nerve deficits developed in three patients. Nettel et al. 15 extended the series of Huang et al., and reported a tumor control rate of 91% after a median follow-up period of 40 months, and noted that 9% of the patients developed new or worsening cranial neuropathies.
Our data show that after a median imaging follow-up period of 37 months (Ն 2 years in all patients), 95% tumor control was achieved, and after a median clinical follow-up period of 46 months, two thirds of patients with preexisting facial pain and one third with trigeminal hypesthesia improved. This is a satisfactory outcome, even compared with those of recent surgical series. Nevertheless, new or worsening cranial neuropathies developed in 27% of patients. Although it is a relatively smaller figure compared with the outcomes of earlier surgical series, it is actually not a small percentage.
Ostensibly, tumor expansion in the cavernous sinus was the proximate cause of cranial neuropathies, and a loss of central contrast enhancement heralded or coincided with tumor expansion and the emergence of cranial neuropathies. Central enhancement loss and transient tumor expansion are typical responses of schwannomas to stereotactic radiosurgery. Studies on the stereotactic radiosurgery of vestibular schwannomas have revealed that as many as 72 to 88% of patients show central enhancement loss and 14 to 64% have tumor expansion. 6, 14, 17, 19, 21 Regis et al. 21 interpreted these two phenomena as favorable signs for radiosurgical efficacy. Yu et al. 24 also found that central enhancement loss and tumor expansion were closely related and that they were usually followed by tumor shrinkage. Pollock 19 observed that 93% of patients with tumor expansion after vestibular schwannoma radiosurgery also showed central enhancement loss and that tumor expansion rarely denoted a failed treatment, because the majority of the tumors (86%) eventually regressed or stopped growing. These authors recommended a conservative approach to this situation, and stressed that if cranial nerve deficits develop they are usually transient. However, in 20% of their patients with tumor expansion, cranial neuropathies developed at the time of initial expansion, and half of the patients required repeated operation.
Our data indicate that the risk of cranial neuropathies at the time of tumor expansion is higher for trigeminal than vestibular schwannomas. Ten patients in our study showed tumor expansion after radiosurgery, and in five of them (50%) cranial neuropathies developed. Why then are cranial nerves more vulnerable to tumor expansion after trigeminal schwannoma radiosurgery? The cavernous sinus is a confined space and cranial nerve entrapment is more likely there than in the posterior fossa when tumor expansion occurs. Actually, no tumor outside the cavernous sinus (posterior fossa or temporal fossa) caused cranial neuropathies in our study, even though tumor expansion occurred in such cases.
In the series published by Pollock et al., 20 who found a similar rate of cranial neuropathies (30%) to ours, they prescribed a relatively high marginal dose (18 Gy). Nettel et al. 15 suggested that, according to their initial experiences, a higher marginal dose (15 Gy) led to two cases of cranial neuropathy, and accordingly, they recommended the application of a lower dose (13 Gy), as is recommended for vestibular schwannomas. We applied a relatively low marginal dose in this series (13.3 Ϯ 1.3 Gy), but no correlation was observed between the prescribed dose and the emergence of cranial neuropathies. Although it is well established for vestibular schwannomas that a low-dose (12-13 Gy) radiosurgical strategy improves hearing preservation, 16, 18 it is uncertain at present whether dose reduction also favors cranial nerve preservation in trigeminal schwannoma radiosurgery.
It is possible that the development of cranial neuropathies after radiosurgery depends on a complex interaction of factors, such as the sizes of the cavernous sinus and Meckel cave, the susceptibilities of individual nerves, initial tumor volume, and prescription dose. Further study is warranted to elucidate more precisely the causes of cranial nerve deficits and to prevent complications.
Conclusions
Although microsurgical resection is mandatory for large tumors, GKS is an effective treatment for small-to medium-sized trigeminal schwannomas. The tumor control rate achieved using GKS was more than 90% after mediumlength follow-up, and improvements in preexisting symptoms, especially trigeminal pain, were remarkable. Nevertheless, the development of cranial neuropathies after radiosurgery remains a problem, and thus every effort should be made to prevent and reduce such adverse effects and to maximize functional outcomes. Tumor expansion in the cavernous sinus after radiosurgery appears to be the proximate cause of cranial neuropathies. Moreover, because central enhancement loss was frequently found to herald or coincide with tumor expansion and the development of cranial neuropathies, it could be used as a warning sign of potential adverse effects. Vigilant patient monitoring and the prompt use of steroids are required if this sign is observed. Further studies with longer follow-up periods are required to define optimal radiosurgical strategies and to evaluate long-term outcomes.
